专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010007116A3 PYRIDONS AS PDK1 INHIBITORS 审中-公开
标题翻译： PYRIDONS作为PDK1抑制剂
公开(公告)号：WO2010007116A3
公开(公告)日：2010-06-17
申请号：PCT/EP2009059114
申请日：2009-07-15
申请人： BOEHRINGER INGELHEIM INT , ENGELHARDT HARALD , BOEHMELT GUIDO , KOFINK CHRISTIANE , KUHN DANIEL , MCCONNELL DARRYL , STADTMUELLER HEINZ
发明人： ENGELHARDT HARALD , BOEHMELT GUIDO , KOFINK CHRISTIANE , KUHN DANIEL , MCCONNELL DARRYL , STADTMUELLER HEINZ
IPC分类号： C07D401/12 , A61K31/435 , A61P35/00 , C07D401/04 , C07D401/14 , C07D487/04
CPC分类号： C07D401/12 , C07D401/04 , C07D401/14 , C07D487/04
摘要： The present invention encompasses compounds of general formula (1) while the groups R4 to R7 and the units W, L, Qa and QH are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use as medicaments having the above-mentioned properties.
摘要翻译：本发明包括通式（1）的化合物，而基团R4至R7和单元W，L，Qa和QH如权利要求1中所定义，其适用于治疗以细胞增殖过度或异常为特征的疾病，并且其用作具有上述性质的药物。

2. 发明申请

WO2010007114A3 HETEROCYCLYL CARBONIC ACID AMIDES AS ANTIPROLIFERATIVE AGENTS, PDKL INHIBITORS 审中-公开
标题翻译：作为抗增生剂的间苯二酚类碳酸钠，PDKL抑制剂
公开(公告)号：WO2010007114A3
公开(公告)日：2010-03-11
申请号：PCT/EP2009059112
申请日：2009-07-15
申请人： BOEHRINGER INGELHEIM INT , ENGELHARDT HARALD , BOEHMELT GUIDO , KOFINK CHRISTIANE , KUHN DANIEL , MCCONNELL DARRYL , STADTMUELLER HEINZ
发明人： ENGELHARDT HARALD , BOEHMELT GUIDO , KOFINK CHRISTIANE , KUHN DANIEL , MCCONNELL DARRYL , STADTMUELLER HEINZ
IPC分类号： C07D213/64 , A61K31/497 , A61P35/00 , C07D401/14 , C07D403/14 , C07D471/04
CPC分类号： C07D471/04 , C07D213/64 , C07D401/14 , C07D403/14
摘要： The present invention encompasses compounds of general formula (1) wherein the units W, A, L, Qa and QH are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use as medicaments having the above-mentioned properties.
摘要翻译：本发明包括通式（1）的化合物，其中单元W，A，L，Qa和QH如权利要求1中所定义，其适用于治疗以细胞增殖过度或异常为特征的疾病，其用途为具有上述特性的药物。

3. 发明申请

WO2008152014A2 NEW COMPOUNDS 审中-公开
标题翻译：新化合物
公开(公告)号：WO2008152014A2
公开(公告)日：2008-12-18
申请号：PCT/EP2008057150
申请日：2008-06-09
申请人： BOEHRINGER INGELHEIM INT , ENGELHARDT HARALD , BETZEMEIER BODO , BOEHMELT GUIDO , GUERTLER ULRICH , KARNER THOMAS , KRAEMER OLIVER , KUHN DANIEL , QUANT JENS JUERGEN , REISER ULRICH , SCHAAF OTMAR , SOLCA FLAVIO , STADTMUELLER HEINZ , TONTSCH-GRUNT ULRIKE , TREU MATTHIAS , ZAHN STEPHAN KARL
发明人： ENGELHARDT HARALD , BETZEMEIER BODO , BOEHMELT GUIDO , GUERTLER ULRICH , KARNER THOMAS , KRAEMER OLIVER , KUHN DANIEL , QUANT JENS JUERGEN , REISER ULRICH , SCHAAF OTMAR , SOLCA FLAVIO , STADTMUELLER HEINZ , TONTSCH-GRUNT ULRIKE , TREU MATTHIAS , ZAHN STEPHAN KARL
IPC分类号： C07D403/04 , A61K31/4184 , A61K31/4985 , A61K31/536 , A61P35/00 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04
CPC分类号： C07D403/04 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D513/04
摘要： The present invention encompasses compounds of general Formula (I) wherein R2, R3, Q, W, X, Y and Z are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
摘要翻译：本发明包括通式（I）的化合物，其中R 2，R 3，Q，W，X，Y和Z如权利要求1中所定义，其适用于治疗以细胞增殖过度或异常为特征的疾病，其用途是制备具有上述性质的药物。

4. 发明申请

WO2008003766A3 4-HETER0CYCL0ALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS 审中-公开
标题翻译： 4-HETER0CYCL0ALKYLPYRI（MI）DINES，其制备方法及其作为药物使用
公开(公告)号：WO2008003766A3
公开(公告)日：2008-02-28
申请号：PCT/EP2007056853
申请日：2007-07-05
申请人： BOEHRINGER INGELHEIM INT , ENGELHARDT HARALD , BADER GERD , BOEHMELT GUIDO , BRUECKNER RALPH , GERSTBERGER THOMAS , IMPAGNATIELLO MARIA , KUHN DANIEL , SCHAAF OTMAR , STADTMUELLER HEINZ , WAIZENEGGER IRENE , ZOEPHEL ANDREAS
发明人： ENGELHARDT HARALD , BADER GERD , BOEHMELT GUIDO , BRUECKNER RALPH , GERSTBERGER THOMAS , IMPAGNATIELLO MARIA , KUHN DANIEL , SCHAAF OTMAR , STADTMUELLER HEINZ , WAIZENEGGER IRENE , ZOEPHEL ANDREAS
IPC分类号： C07D471/04 , C07D487/04 , C07D519/00
CPC分类号： C07D471/04 , C07D487/04 , C07D519/00
摘要： The present invention encompasses compounds of general Formula (I) wherein X and R 1 to R 3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
摘要翻译：本发明包括通式（I）的化合物，其中X和R 1至R 3定义如权利要求1，其适用于治疗特征为过度或异常细胞增殖，以及其用于制备具有上述性质的药物组合物的用途。

5. 发明申请

WO2008077885A3 2- [(PHENYLAMINO) -PYRIMIDIN-4YLAMIN0] -CYCLOPENTANE CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF KINASES OF THE CELL CYCLE FOR THE TREATMENT OF CANCER 审中-公开
标题翻译： 2- [（苯甲酰胺基） - 嘧啶-4-基]胺]羧酰胺衍生物及相关化合物作为细胞周期的细胞因子的抑制剂治疗癌症
公开(公告)号：WO2008077885A3
公开(公告)日：2008-08-14
申请号：PCT/EP2007064342
申请日：2007-12-20
申请人： BOEHRINGER INGELHEIM INT , ZAHN STEPHAN , BOEHMELT GUIDO , GUERTLER ULRICH , MANTOULIDIS ANDREAS , SCHOOP ANDREAS , SOLCA FLAVIO , TONTSCH-GRUNT ULRIKE , TREU MATTHIAS
发明人： ZAHN STEPHAN , BOEHMELT GUIDO , GUERTLER ULRICH , MANTOULIDIS ANDREAS , SCHOOP ANDREAS , SOLCA FLAVIO , TONTSCH-GRUNT ULRIKE , TREU MATTHIAS
IPC分类号： C07D239/48 , A61K31/505 , A61P35/00
CPC分类号： C07D239/48 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14
摘要： The present invention encompassescompounds of general formula (1) wherein R 1 to R 4 , X and n are defined as in claim 1, which are suitable for the treatment of ailments characterised byexcessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
摘要翻译：本发明包括通式（1）的化合物，其中R 1至R 4，X和n如权利要求1中所定义，其适用于治疗特征性疾病过度或异常的细胞增殖，以及其用于制备具有上述性质的药物的用途。

6. 发明专利

BRPI0712400A2 未知
公开(公告)号：BRPI0712400A2
公开(公告)日：2012-10-16
申请号：BRPI0712400
申请日：2007-05-15
申请人： BOEHRINGER INGELHEIM INT
发明人： ZAHN STEPHAN KARL , BISTER BOJAN , BOEHMELT GUIDO , GUERTLER ULRICH , MANTOULIDIS ANDREAS , REISER ULRICH , SCHOOP ANDREAS , SOLCA FLAVIO , TONTSCH-GRUNT ULRIKE , TREU MATTHIAS
IPC分类号： C07D401/12 , A61K31/506 , A61P35/00 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/14 , C07D417/14
摘要： 2,4-Diamino pyrimidine compounds (I) and their tautomers, racemates, enantiomers and/or diastereomers, and optionally their acid addition salts, are new. 2,4-Diamino pyrimidine compounds of formula (I) and their tautomers, racemates, enantiomers and/or diastereomers, and optionally their acid addition salts, are new. X : N or CH; R 1>3-10C cycloalkyl (substituted with R 3> and optionally with one or more R 4>); R 2>H, halo, -CN, -NO 2, 1-4C (halo)alkyl, 3-10C cycloalkyl, 4-16C cycloalkylalkyl or 7-16C arylalkyl; R 3>-C(O)Rc, -C(O)ORC, -C(O)NRCRC, -S(O)2RC, -N(Rf)S(O)2Rc, -N(Rf)C(O)Rc, -N(Rf)C(O)ORc or -N(Rf)C(O)NRcRc; R 4>Ra or Rb (where Ra is substituted by Rc and/or Rb); Ra : 1-6C alkyl, 3-10C cycloalkyl, 4-16C cycloalkylalkyl, 6-10C aryl, 7-16C arylalkyl, 2-6 membered heteroalkyl, 3-8 membered heterocycloalkyl, 4-14 membered heterocycloalkylalkyl, 5-12 membered heteroaryl or 6-18 membered heteroarylalkyl; Rb : O=, -ORc, 1-3C haloalkyloxy, -OCF 3, =S, -SRc, =NRc, =NORc, -NRcRc, halo, -CF 3, -CN, -NC, -OCN, -SCN, -NO 2, -S(O)Rc, -S(O) 2Rc, -S(O) 2ORc, -S(O)NRcRc, -S(O) 2NRcRc, -OS(O)Rc, -OS(O) 2Rc, -OS(O) 2ORc, -OS(O) 2NRcRc, -C(O)Rc, -C(O)ORc, -C(O)NRcRc, -CN(Rf)NRcRc, -CN(OH)Rc, -CN(OH)NRcRc, -OC(O)Rc, -OC(O)ORc, -OC(O)NRcRc, -OCN(Rf)NRcRc, -N(Rf)C(O)Rc, -N(Rf)C(S)Rc, -N(Rf)S(O) 2Rc, -N(Rf)C(O)ORc, -N(Rf)C(O)NRcRc, -[N(Rf)C(O)] 2Rc, -N[C(O)] 2Rc, -N[C(O)] 2ORc, -[N(Rf)C(O)] 2ORc or -N(Rf)CN(Rf)NRcRc; Rc : H or optionally Rd and/or Re substituted 1-6C alkyl, 3-10C cycloalkyl, 4-11C cycloalkylalkyl, 6-10C aryl, 7-16C arylalkyl, 2-6 membered heteroalkyl, 3-8 membered heterocycloalkyl, 4-14 membered heterocycloalkylalkyl, 5-12 membered heteroaryl or 6-18 membered heteroarylalkyl; Rd : H or an optionally Re and/or Rf substituted 1-6C alkyl, 3-8C cycloalkyl, 4-11C cycloalkylalkyl, 6-10C aryl, 7-16C arylalkyl, 2-6 membered heteroalkyl, 3-8 membered heterocycloalkyl, 4-14 membered heterocycloalkylalkyl, 5-12 membered heteroaryl or 6-18 membered heteroarylalkyl; Re : O=, -OR, 1-3C haloalkyloxy, -OCF 3, =S, -SR , =NR, =NORf, -NRfRf, halo, -CF-3, -CN, -NC, -OCN, -SCN, -NO 2, -S(O)Rf, -S(O) 2Rf, -S(O) 2ORf, -S(O)NRfRf, -S(O) 2NRfRf, -OS(O)Rf, -OS(O) 2Rf, -OS(O) 2ORf, -OS(O) 2NRfRf, -C(O)Rf, -C(O)ORf, -C(O)NRfRf, -CN(Rg)NRfRf, -CN(OH)Rf, -C(NOH)NRfRf, -OC(O)Rf, -OC(O)ORf, -OC(O)NRfRf, -OCN(Rg)NRfRf, -N(Rg)C(O)Rf, -N(Rg)C(S)Rf, -N(Rg)S(O) 2Rf, -N(Rd)C(O)ORf, -N(Rg)C(O)NRfRf or -N(Rg)CN(Rf)NRfRf; Rf : H or optionally Rg substituted 1-6C alkyl, 3-8C cycloalkyl, 4-11C cycloalkylalkyl, 6-10C aryl, 7-16C arylalkyl, 2-6 membered heteroalkyl, 3-8 membered heterocycloalkyl, 4-14 membered heterocycloalkylalkyl, 5-12 membered heteroaryl or 6-18 membered heteroarylalkyl; Rg : H, 1-6C alkyl, 3-8C cycloalkyl, 4-11C cycloalkylalkyl, 6-10C aryl, 7-16C arylalkyl, 2-6 membered heteroalkyl, 3-8 membered heterocycloalkyl, 4-14 membered heterocycloalkyl, 5-12 membered heteroaryl or 6-18 membered heteroarylalkyl; m : 0 or 1; n : 1-4; and p : 0-2. Provided that 25 compounds are excluded e.g. 4-[4-((1R,2S)-2-isopropylcarbamoyl-cyclopentylamino)-5-trifluoromethylpyrimidine-2-ylamino]-N-( 1-methyl-piperidin-4-yl)-benzamide, 4-[4-((1R,2S)-2-isopropylcarbamoyl-cyclopentylamino)-5-trifluoromethylpyrimidin-2-ylamino]-N-piperidin-4-yl-benzamide, 2-chloro-4-[4-((1R,2S)-2-isopropylcarbamoyl-cyclopentylamino)-5-trifluoromethylpyrimidin-2-ylamino]-N-methyl-N-(1-methyl-piperidin-4-yl)-benzamide, 4-[4-((1R,2S)-2-carbamoyl-cyclopentylamino)-5-methyl-pyrimidin-2-ylamino]-N-(1-methyl-piperidin-4-yl)-benzamide and 4-[4-((1R,2S)-2-carbamoyl-cyclopentylamino)-5-nitro-pyrimidin-2-ylamino]-N-(1-methyl-piperidin-4-yl)-benzamide. An independent claim is included for a pharmaceutical preparation comprising (I) and at least a further cytostatic or cytotoxic active substance. [Image] ACTIVITY : Cytostatic; Antimicrobial; Antiinflammatory; Immunosuppressive; Anti-HIV; Gastrointestinal-Gen; Antiarthritic; Neuroprotective; Nootropic; Nephrotropic; Vulnerary; Dermatological; Antipsoriatic; Cardiovascular-Gen; Vasotropic. MECHANISM OF ACTION : Cell cycle kinase inhibitor.

7. 发明专利

AT545641T 未知
公开(公告)号：AT545641T
公开(公告)日：2012-03-15
申请号：AT07729171
申请日：2007-05-15
申请人： BOEHRINGER INGELHEIM INT
发明人： ZAHN STEPHAN KARL , BISTER BOJAN , BOEHMELT GUIDO , GUERTLER ULRICH , MANTOULIDIS ANDREAS , REISER ULRICH , SCHOOP ANDREAS , SOLCA FLAVIO , TONTSCH-GRUNT ULRIKE , TREU MATTHIAS
IPC分类号： C07D401/12 , A61K31/506 , A61P35/00 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/14 , C07D417/14
摘要： 2,4-Diamino pyrimidine compounds (I) and their tautomers, racemates, enantiomers and/or diastereomers, and optionally their acid addition salts, are new. 2,4-Diamino pyrimidine compounds of formula (I) and their tautomers, racemates, enantiomers and/or diastereomers, and optionally their acid addition salts, are new. X : N or CH; R 1>3-10C cycloalkyl (substituted with R 3> and optionally with one or more R 4>); R 2>H, halo, -CN, -NO 2, 1-4C (halo)alkyl, 3-10C cycloalkyl, 4-16C cycloalkylalkyl or 7-16C arylalkyl; R 3>-C(O)Rc, -C(O)ORC, -C(O)NRCRC, -S(O)2RC, -N(Rf)S(O)2Rc, -N(Rf)C(O)Rc, -N(Rf)C(O)ORc or -N(Rf)C(O)NRcRc; R 4>Ra or Rb (where Ra is substituted by Rc and/or Rb); Ra : 1-6C alkyl, 3-10C cycloalkyl, 4-16C cycloalkylalkyl, 6-10C aryl, 7-16C arylalkyl, 2-6 membered heteroalkyl, 3-8 membered heterocycloalkyl, 4-14 membered heterocycloalkylalkyl, 5-12 membered heteroaryl or 6-18 membered heteroarylalkyl; Rb : O=, -ORc, 1-3C haloalkyloxy, -OCF 3, =S, -SRc, =NRc, =NORc, -NRcRc, halo, -CF 3, -CN, -NC, -OCN, -SCN, -NO 2, -S(O)Rc, -S(O) 2Rc, -S(O) 2ORc, -S(O)NRcRc, -S(O) 2NRcRc, -OS(O)Rc, -OS(O) 2Rc, -OS(O) 2ORc, -OS(O) 2NRcRc, -C(O)Rc, -C(O)ORc, -C(O)NRcRc, -CN(Rf)NRcRc, -CN(OH)Rc, -CN(OH)NRcRc, -OC(O)Rc, -OC(O)ORc, -OC(O)NRcRc, -OCN(Rf)NRcRc, -N(Rf)C(O)Rc, -N(Rf)C(S)Rc, -N(Rf)S(O) 2Rc, -N(Rf)C(O)ORc, -N(Rf)C(O)NRcRc, -[N(Rf)C(O)] 2Rc, -N[C(O)] 2Rc, -N[C(O)] 2ORc, -[N(Rf)C(O)] 2ORc or -N(Rf)CN(Rf)NRcRc; Rc : H or optionally Rd and/or Re substituted 1-6C alkyl, 3-10C cycloalkyl, 4-11C cycloalkylalkyl, 6-10C aryl, 7-16C arylalkyl, 2-6 membered heteroalkyl, 3-8 membered heterocycloalkyl, 4-14 membered heterocycloalkylalkyl, 5-12 membered heteroaryl or 6-18 membered heteroarylalkyl; Rd : H or an optionally Re and/or Rf substituted 1-6C alkyl, 3-8C cycloalkyl, 4-11C cycloalkylalkyl, 6-10C aryl, 7-16C arylalkyl, 2-6 membered heteroalkyl, 3-8 membered heterocycloalkyl, 4-14 membered heterocycloalkylalkyl, 5-12 membered heteroaryl or 6-18 membered heteroarylalkyl; Re : O=, -OR, 1-3C haloalkyloxy, -OCF 3, =S, -SR , =NR, =NORf, -NRfRf, halo, -CF-3, -CN, -NC, -OCN, -SCN, -NO 2, -S(O)Rf, -S(O) 2Rf, -S(O) 2ORf, -S(O)NRfRf, -S(O) 2NRfRf, -OS(O)Rf, -OS(O) 2Rf, -OS(O) 2ORf, -OS(O) 2NRfRf, -C(O)Rf, -C(O)ORf, -C(O)NRfRf, -CN(Rg)NRfRf, -CN(OH)Rf, -C(NOH)NRfRf, -OC(O)Rf, -OC(O)ORf, -OC(O)NRfRf, -OCN(Rg)NRfRf, -N(Rg)C(O)Rf, -N(Rg)C(S)Rf, -N(Rg)S(O) 2Rf, -N(Rd)C(O)ORf, -N(Rg)C(O)NRfRf or -N(Rg)CN(Rf)NRfRf; Rf : H or optionally Rg substituted 1-6C alkyl, 3-8C cycloalkyl, 4-11C cycloalkylalkyl, 6-10C aryl, 7-16C arylalkyl, 2-6 membered heteroalkyl, 3-8 membered heterocycloalkyl, 4-14 membered heterocycloalkylalkyl, 5-12 membered heteroaryl or 6-18 membered heteroarylalkyl; Rg : H, 1-6C alkyl, 3-8C cycloalkyl, 4-11C cycloalkylalkyl, 6-10C aryl, 7-16C arylalkyl, 2-6 membered heteroalkyl, 3-8 membered heterocycloalkyl, 4-14 membered heterocycloalkyl, 5-12 membered heteroaryl or 6-18 membered heteroarylalkyl; m : 0 or 1; n : 1-4; and p : 0-2. Provided that 25 compounds are excluded e.g. 4-[4-((1R,2S)-2-isopropylcarbamoyl-cyclopentylamino)-5-trifluoromethylpyrimidine-2-ylamino]-N-( 1-methyl-piperidin-4-yl)-benzamide, 4-[4-((1R,2S)-2-isopropylcarbamoyl-cyclopentylamino)-5-trifluoromethylpyrimidin-2-ylamino]-N-piperidin-4-yl-benzamide, 2-chloro-4-[4-((1R,2S)-2-isopropylcarbamoyl-cyclopentylamino)-5-trifluoromethylpyrimidin-2-ylamino]-N-methyl-N-(1-methyl-piperidin-4-yl)-benzamide, 4-[4-((1R,2S)-2-carbamoyl-cyclopentylamino)-5-methyl-pyrimidin-2-ylamino]-N-(1-methyl-piperidin-4-yl)-benzamide and 4-[4-((1R,2S)-2-carbamoyl-cyclopentylamino)-5-nitro-pyrimidin-2-ylamino]-N-(1-methyl-piperidin-4-yl)-benzamide. An independent claim is included for a pharmaceutical preparation comprising (I) and at least a further cytostatic or cytotoxic active substance. [Image] ACTIVITY : Cytostatic; Antimicrobial; Antiinflammatory; Immunosuppressive; Anti-HIV; Gastrointestinal-Gen; Antiarthritic; Neuroprotective; Nootropic; Nephrotropic; Vulnerary; Dermatological; Antipsoriatic; Cardiovascular-Gen; Vasotropic. MECHANISM OF ACTION : Cell cycle kinase inhibitor.

8. 发明专利

MY142496A 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS 未知
公开(公告)号：MY142496A
公开(公告)日：2010-11-30
申请号：MYPI20063091
申请日：2006-06-28
申请人： BOEHRINGER INGELHEIM INT
发明人： ZAHN STEPHAN KARL , BRUECKNER RALPH , REITHER CHARLOTTE , HERFURTH LARS , KRAEMER OLIVER , STADTMUELLER HEINZ , ENGELHARDT HARALD , BOEHMELT GUIDO , MANTOULIDIS ANDREAS , REISER ULRICH , TREU MATTHIAS , GUERTLER ULRICH , SCHOOP ANDREAS , SOLCA FLAVIO , TONTSCH-GRUNT ULRIKE
IPC分类号： C07D239/48
摘要： 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS THE PRESENT INVENTION ENCOMPASSES COMPOUNDS OF GENERAL FORMULA (1) R 3 H RLZ@LR N@ R N N HN@ R 2 5 WHEREIN R ITO R 3ARE DEFINED AS IN CLAIM 1, WHICH ARE SUITABLE FOR THE TREATMENT OF DISEASES CHARACTERISED BY EXCESSIVE OR ABNORMAL CELL PROLIFERATION, AND THE USE THEREOF FOR PREPARING A PHARMACEUTICAL COMPOSITION HAVING THE ABOVE-MENTIONED PROPERTIES. 10

9. 发明专利

CA2729986A1 NEW CHEMICAL COMPOUNDS 未知
公开(公告)号：CA2729986A1
公开(公告)日：2010-01-21
申请号：CA2729986
申请日：2009-07-15
申请人： BOEHRINGER INGELHEIM INT
发明人： ENGELHARDT HARALD , BOEHMELT GUIDO , KOFINK CHRISTIANE , KUHN DANIEL , MCCONNELL DARRYL , STADTMUELLER HEINZ
IPC分类号： C07D213/64 , A61K31/497 , A61P35/00 , C07D401/14 , C07D403/14 , C07D471/04
摘要： The present invention encompasses compounds of general formula (1) wherein the units W, A, L, Qa and QH are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use as medicaments having the above-mentioned properties.

10. 发明专利

DE502006004750D1 未知
公开(公告)号：DE502006004750D1
公开(公告)日：2009-10-15
申请号：DE502006004750
申请日：2006-06-30
申请人： BOEHRINGER INGELHEIM PHARMA , BOEHRINGER INGELHEIM INT
发明人： ZAHN STEPHAN KARL , BOEHMELT GUIDO , MANTOULIDIS ANDREAS , REISER ULRICH , TREU MATTHIAS , GUERTLER ULRICH , SCHOOP ANDREAS , SOLCA FLAVIO , TONTSCH-GRUNT ULRIKE , BRUECKNER RALPH , REITHER CHARLOTTE , HERFURTH LARS , KRAEMER OLIVER , STADTMUELLER HEINZ , ENGELHARDT HARALD
IPC分类号： C07D239/48 , A61K31/505 , A61P31/00 , A61P35/00
摘要： The present invention encompasses compounds of general formula (1) wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式